Please ensure Javascript is enabled for purposes of website accessibility

Why Agenus Stock Tumbled Today

By Keith Speights - May 6, 2021 at 3:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced mixed Q1 results on a day when many biotech stocks were sinking.

What happened

Shares of Agenus (AGEN -1.51%) were tumbling 4.9% lower as of 3:44 p.m. EDT on Thursday after falling as much as 7.5% earlier in the day. The decline came after the company provided its first-quarter update before the market opened.

So what

Agenus reported revenue of $11.7 million in the first quarter, all of which stemmed from its collaborations with other drugmakers. This result fell short of the average analysts' revenue estimate of $14.5 million. The company posted a net loss of $54.4 million, or $0.27 per share. The consensus analysts' estimate was for a net loss in Q1 of $0.31 per share.

Scientist looking through a microscope

Image source: Getty Images.

Those mixed first-quarter results might not have been the only culprit behind the pullback for Agenus, though. Biotech stocks, in general, fell on Thursday, in part because of concerns about the potential impact of the Biden administration's support of waiving intellectual property rights for COVID-19 vaccines to increase the availability of the vaccines in poorer countries.

Now what

The primary potential catalyst for Agenus now is the anticipated U.S. Food and Drug Administration (FDA) accelerated approval for balstilimab in treating cervical cancer. Agenus filed for FDA approval of the drug in April.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
AGEN
$2.61 (-1.51%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.